Investor alert: investigation of savara inc. (svra) announced by holzer & holzer, llc

Atlanta, may 27, 2025 (globe newswire) -- holzer & holzer, llc is investigating whether savara inc. (“savara” or the “company”) (nasdaq: svra) complied with federal securities laws. on may 27, 2025, savara announced that it had received a refusal to file letter from the fda for the biologics license application of molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. following this news, the price of the company's stock dropped.
SVRA Ratings Summary
SVRA Quant Ranking